←Back to Expert Scholars
Translational Medicine / 转化医学Ovarian Cancer, Study 19 Olaparib
Jonathan Ledermann
MD
🏢University College London🌐UK
Professor of Medical Oncology
90
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Jonathan Ledermann led the original Study 19 and SOLO-2 trials establishing olaparib as maintenance therapy for platinum-sensitive recurrent ovarian cancer. His pivotal work supported the first PARP inhibitor regulatory approvals worldwide. He continues to lead GCIG consensus conferences on ovarian cancer.
Share:
🧪Research Fields 研究领域
Study 19 olaparib
SOLO-2
platinum-sensitive relapse
PARP inhibitor registration
ICON trials
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Jonathan Ledermann 的研究动态
Follow Jonathan Ledermann's research updates
留下邮箱，当我们发布与 Jonathan Ledermann（University College London）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment